Brief: Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence

Astellas Pharma

10/07/2025 11:52

July 10 (Reuters) - Pfizer Inc PFE.N:

XTANDI® PLUS LEUPROLIDE SIGNIFICANTLY IMPROVES SURVIVAL OUTCOMES IN MEN WITH NON-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH HIGH-RISK BIOCHEMICAL RECURRENCE

PFIZER: EMBARK MET KEY SECONDARY ENDPOINT

PFIZER INC - XTANDI PLUS LEUPROLIDE IMPROVES OVERALL SURVIVAL

PFIZER: NO NEW SAFETY SIGNALS WERE OBSERVED IN ANALYSIS, AND SAFETY RESULTS WERE CONSISTENT WITH DEMONSTRATED SAFETY PROFILE OF XTANDI

Source text: ID:nBw5fldBDa

Further company coverage: PFE.N

 ((Reuters.Briefs@thomsonreuters.com;))